# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Dae Gon Ha maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $204 to $220.
Cantor Fitzgerald analyst Josh Schimmer reiterates Krystal Biotech (NASDAQ:KRYS) with a Overweight.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $221 pric...
HC Wainwright & Co. analyst Joseph Pantginis maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price tar...